BR112022015326A2 - Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante - Google Patents

Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante

Info

Publication number
BR112022015326A2
BR112022015326A2 BR112022015326A BR112022015326A BR112022015326A2 BR 112022015326 A2 BR112022015326 A2 BR 112022015326A2 BR 112022015326 A BR112022015326 A BR 112022015326A BR 112022015326 A BR112022015326 A BR 112022015326A BR 112022015326 A2 BR112022015326 A2 BR 112022015326A2
Authority
BR
Brazil
Prior art keywords
von willebrand
patients
administration
treatment
menorrhagia
Prior art date
Application number
BR112022015326A
Other languages
English (en)
Inventor
Ploder Bettina
Truong-Berthoz Françoise
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112022015326A2 publication Critical patent/BR112022015326A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

TRATAMENTO DE MENORRAGIA EM PACIENTES COM DOENÇA DE VON WILLEBRAND SEVERA POR ADMINISTRAÇÃO DE VWF RECOMBINANTE. A presente invenção se refere a um método para tratamento de menorragia em um sujeito com Doença de von Willebrand (VWD) severa compreendendo administrar uma quantidade terapêutica de fator de von Willebrand recombinante (rVWF) ao sujeito.
BR112022015326A 2020-02-04 2021-02-04 Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante BR112022015326A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062969998P 2020-02-04 2020-02-04
PCT/US2021/016592 WO2021158777A1 (en) 2020-02-04 2021-02-04 Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Publications (1)

Publication Number Publication Date
BR112022015326A2 true BR112022015326A2 (pt) 2022-10-11

Family

ID=74759563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015326A BR112022015326A2 (pt) 2020-02-04 2021-02-04 Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante

Country Status (12)

Country Link
US (1) US20230398188A1 (pt)
EP (1) EP4100048A1 (pt)
JP (1) JP2023514541A (pt)
KR (1) KR20220150303A (pt)
CN (1) CN115335074A (pt)
AR (1) AR121268A1 (pt)
AU (1) AU2021216945A1 (pt)
BR (1) BR112022015326A2 (pt)
CA (1) CA3169996A1 (pt)
MX (1) MX2022009492A (pt)
TW (1) TW202134266A (pt)
WO (1) WO2021158777A1 (pt)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PT1835938E (pt) 2004-12-27 2013-11-06 Baxter Int Conjugados de polímero-factor de von willebrand
PL2522717T3 (pl) 2006-01-04 2014-08-29 Baxalta Inc Pożywki do hodowli komórkowych wolne od oligopeptydów
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
BR112013000515B1 (pt) 2010-07-08 2021-11-03 Takeda Pharmaceutical Company Limited Método para produzir uma composição de fator von willebrand recombinante (rvwf)
KR101969515B1 (ko) 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료

Also Published As

Publication number Publication date
WO2021158777A1 (en) 2021-08-12
TW202134266A (zh) 2021-09-16
KR20220150303A (ko) 2022-11-10
CA3169996A1 (en) 2021-08-12
JP2023514541A (ja) 2023-04-06
US20230398188A1 (en) 2023-12-14
AU2021216945A1 (en) 2022-09-01
CN115335074A (zh) 2022-11-11
AR121268A1 (es) 2022-05-04
EP4100048A1 (en) 2022-12-14
MX2022009492A (es) 2022-11-09

Similar Documents

Publication Publication Date Title
BR112019001573A2 (pt) conjunto de componentes e dispositivos para aplicação de terapia de luz e métodos relacionados aos mesmos
RU2012100397A (ru) Препарат, содержащий инсулин, никотинамид и аминокислоту
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
BR112022016100A2 (pt) Composição farmacêutica compreendendo microgrânulos de liberação sustentada incluindo análogo de glp-1 ou sal farmaceuticamente aceitável do mesmo
BR112014021653A2 (pt) Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica
Vescovi Bisphosphonates and osteonecrosis: an open matter
RU2013130374A (ru) Препарат, содержащий инсулин, никотинамид и аминокислоту
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
BR112022015326A2 (pt) Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante
BR112013007198A2 (pt) peptídeos do veneno do escorpião rhopalurus junceus e composições farmacêuticas
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante
RU2008126108A (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
BR112019004210A2 (pt) composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento
CO2020001322A2 (es) Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
AR072120A1 (es) Fenil-alquil-piperazinas que tienen actividad moduladora de tnf, un proceso de preparacion del compuesto, una composicion farmaceutica que lo contiene, un medicamento en base al compuesto y la utilizacion del compuesto para preparar un medicamento
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
BR112014001538A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para tratamento de doenças retinais
BR112022002444A2 (pt) Técnicas de sobremoldagem e artigos relacionados produzidos por estas
BR112018016817A2 (pt) composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento
RU2710541C1 (ru) Способ лечения ангулярного хейлита, возникшего вследствие дефицита рибофлавина
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
BR112015009291A2 (pt) métodos para o controle da pressão arterial e redução da dispnéia na insuficiência cardíaca
Sharifnia et al. Effect of ephedrine on pain and hemodynamic status on injection of propofol